Canopy Growth Corporation Common Shares (CGC) — 分析摘要
Canopy Growth Corporation Common Shares(CGC)的市值为320.45百万美元,最近一年的营收同比增长了+6.9%。净利润率为-92.4%。当前市盈率为-1.7倍。
核心要点
- 营收同比变化+6.9%
- 净利润率-92.4%
- 市盈率-1.7倍
与MEDICINAL CHEMICALS & BOTANICAL PRODUCTS板块的其他公司相比,CGC的营收增长为+6.9%,市盈率为-1.7倍。
Canopy Growth Corporation Common Shares (CGC)
前收盘价 2026-10-12 · 市场数据 POLYGON · 财务数据 SEC EDGAR
红旗与风险提示高风险信号
存在多项实质性红旗,在依赖任何估值输出前应先重点核查这些风险。
利息保障倍数为 -4.2x — 盈利不足以覆盖利息支出
营业利润率为 -56.8% — 严重经营亏损
净利率为 -92.4% — 亏损显著
最新报表显示自由现金流为负。
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.
行业
MEDICINAL CHEMICALS & BOTANICAL PRODUCTS
员工人数
1,128
总部
SMITH FALLS, A6
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析,不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
年度每股股息
$0.96
股息收益率
126.73%
股息历史
免责声明:本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。